1
|
Ledoux JM, Brun P, Chapuis T, Dumas P, Guillotin J. Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report. VETERINARY MEDICINE-RESEARCH AND REPORTS 2014; 5:109-113. [PMID: 32670851 PMCID: PMC7337170 DOI: 10.2147/vmrr.s67118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/05/2014] [Accepted: 04/23/2014] [Indexed: 11/29/2022]
Abstract
Feline injection site sarcoma is a common tumor among cats, for which existing medical treatments do not prove to be entirely satisfactory. In this tumor, the platelet-derived growth factor receptor, a tyrosine kinase receptor, is frequently hyperactivated. In the past, clinical case reports with imatinib, a tyrosine kinase inhibitor (TKI), have demonstrated tumoral stabilization. Here we describe the use of another TKI, masitinib, which specifically inhibits c-Kit, platelet-derived growth factor receptor, and Lyn, and is currently licensed for veterinary use in canine mast cell tumors. The therapeutic results were initially satisfactory, with regression of the tumor followed by tumoral recurrence which was stabilized and moderately reduced. Further studies are suggested, in order to evaluate the relevance of TKIs in the treatment and prevention of recurrences of feline injection site sarcoma. Tumoral stabilization by means of an inexpensive and reasonably well tolerated treatment would prove to be of true therapeutic relevance, in particular for inoperable feline injection site sarcomas. Another indication for such TKIs could be in preoperative treatment as a means of facilitating surgical excision by reduction of adhesions.
Collapse
Affiliation(s)
| | | | | | - Paul Dumas
- Laboratoire de Pathologie Vétérinaire du Nord, Annœullin
| | - Jean Guillotin
- Laboratoire Départemental Public, Villeneuve d'Ascq, France
| |
Collapse
|
2
|
Singer J, Fazekas J, Wang W, Weichselbaumer M, Matz M, Mader A, Steinfellner W, Meitz S, Mechtcheriakova D, Sobanov Y, Willmann M, Stockner T, Spillner E, Kunert R, Jensen-Jarolim E. Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients. Mol Cancer Ther 2014; 13:1777-1790. [PMID: 24755200 DOI: 10.1158/1535-7163.mct-13-0288] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuximab in human clinical oncology, we present here a "caninized" version of this antibody, can225IgG, for comparative oncology studies. Variable region genes of 225, the murine precursor of cetuximab, were fused with canine constant heavy gamma and kappa chain genes, respectively, and transfected into Chinese hamster ovary (CHO) DUKX-B11 cells. Of note, 480 clones were screened and the best clones were selected according to productivity and highest specificity in EGFR-coated ELISA. Upon purification with Protein G, the recombinant cetuximab-like canine IgG was tested for integrity, correct assembly, and functionality. Specific binding to the surface of EGFR-overexpressing cells was assessed by flow cytometry and immunofluorescence; moreover, binding to canine mammary tissue was demonstrated by immunohistochemistry. In cell viability and proliferation assays, incubation with can225IgG led to significant tumor cell growth inhibition. Moreover, this antibody mediated significant tumor cell killing via phagocytosis in vitro. We thus present here, for the first time, the generation of a canine IgG antibody and its hypothetical structure. On the basis of its cetuximab-like binding site, on the one hand, and the expression of a 91% homologous EGFR molecule in canine cancer, on the other hand, this antibody may be a promising research compound to establish passive immunotherapy in dog patients with cancer.
Collapse
Affiliation(s)
- Josef Singer
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
- Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna
| | - Judit Fazekas
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
- Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna
- Department for Applied Life Sciences, University of Applied Sciences, FH Campus Wien
| | - Wei Wang
- Department of Immunology, Capital Medical University, Beijing, PR China
| | - Marlene Weichselbaumer
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
- Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna
| | - Miroslawa Matz
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
| | - Alexander Mader
- Department of Biotechnology, VIBT-BOKU, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Willibald Steinfellner
- Department of Biotechnology, VIBT-BOKU, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Sarah Meitz
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
- Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna
| | - Diana Mechtcheriakova
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
| | - Yuri Sobanov
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
| | - Michael Willmann
- Department for Companion Animals and Horses, University of Veterinary Medicine Vienna
| | - Thomas Stockner
- Centre for Physiology and Pharmacology, Medical University of Vienna
| | - Edzard Spillner
- Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany
| | - Renate Kunert
- Department of Biotechnology, VIBT-BOKU, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Erika Jensen-Jarolim
- Comparative Immunology and Oncology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna
- Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna
| |
Collapse
|
3
|
Analysis of activated platelet-derived growth factor β receptor and Ras-MAP kinase pathway in equine sarcoid fibroblasts. BIOMED RESEARCH INTERNATIONAL 2013; 2013:283985. [PMID: 23936786 PMCID: PMC3726019 DOI: 10.1155/2013/283985] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/14/2013] [Revised: 06/03/2013] [Accepted: 06/18/2013] [Indexed: 11/24/2022]
Abstract
Equine sarcoids are skin tumours of fibroblastic origin affecting equids worldwide. Bovine papillomavirus type-1 (BPV-1) and, less commonly, type-2 are recognized as etiological factors of sarcoids. The transforming activity of BPV is related to the functions of its major oncoprotein E5 which binds to the platelet-derived growth factor β receptor (PDGFβR) causing its phosphorylation and activation. In this study, we demonstrate, by coimmunoprecipitation and immunoblotting, that in equine sarcoid derived cell lines PDGFβR is phosphorylated and binds downstream molecules related to Ras-mitogen-activated protein kinase-ERK pathway thus resulting in Ras activation. Imatinib mesylate is a tyrosine kinase receptors inhibitor which selectively inhibits the activation of PDGFβR in the treatment of several human and animal cancers. Here we show that imatinib inhibits receptor phosphorylation, and cell viability assays demonstrate that this drug decreases sarcoid fibroblasts viability in a dose-dependent manner. This study contributes to a better understanding of the molecular mechanisms involved in the pathology of sarcoids and paves the way to a new therapeutic approach for the treatment of this common equine skin neoplasm.
Collapse
|
4
|
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. Vet Immunol Immunopathol 2009; 132:243-50. [PMID: 19505729 DOI: 10.1016/j.vetimm.2009.05.007] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2009] [Revised: 04/19/2009] [Accepted: 05/11/2009] [Indexed: 11/24/2022]
Abstract
Systemic mastocytosis (SM) in felines is a rare neoplasm defined by increased growth and accumulation of immature mast cells (MC) in various organs including the spleen. Although in many cases splenectomy is an effective approach, relapses may occur. In these patients, treatment options are limited. Recent data suggest that various Kit tyrosine kinase inhibitors (TKI) interfere with growth of neoplastic MC in humans. In the current study, we examined the effects of four TKI, imatinib, midostaurin, nilotinib, and dasatinib, on growth of spleen-derived feline neoplastic MC in three SM patients. Expression of Kit in neoplastic MC was confirmed by flow cytometry and/or Western blotting. In all three cases, a 12-bp internal tandem duplication in exon 8, resulting in a four amino acid-insertion between residues Thr418 and His419 in Kit, was detectable. As assessed by (3)H-thymidine incorporation experiments, all four TKI were found to inhibit the growth of feline neoplastic MC in a dose-dependent manner. The growth-inhibitory TKI effects were found to be associated with morphologic signs of apoptosis in MC. In conclusion, various Kit-targeting TKI can inhibit the in vitro growth and survival of feline neoplastic MC in SM.
Collapse
|